

# Kent W Mouw

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1408359/publications.pdf>

Version: 2024-02-01

86  
papers

4,073  
citations

201674

27  
h-index

128289

60  
g-index

87  
all docs

87  
docs citations

87  
times ranked

7873  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 75-82.	0.8	34
2	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	1.9	12
3	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas. <i>Journal of Clinical Oncology</i> , 2022, 40, 1275-1280.	1.6	6
4	<i>RB1</i> loss overrides PARP inhibitor sensitivity driven by <i>RNASEH2B</i> loss in prostate cancer. <i>Science Advances</i> , 2022, 8, eabl9794.	10.3	14
5	Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy. <i>Prostate</i> , 2022, 82, 1098-1106.	2.3	2
6	PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	5.4	9
7	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 201-208.	1.6	2
8	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	7.0	19
9	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021, 11, e426-e433.	2.1	3
10	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1-9.	0.5	0
11	Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes. <i>Molecular Cancer Research</i> , 2021, 19, 1308-1321.	3.4	8
12	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021, 127, 2213-2221.	4.1	9
13	Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3734-3743.	7.0	17
14	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	7.0	51
15	Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 567-584.	2.2	8
16	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3851-3857.	1.1	1
17	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021, 161, 241-250.	0.6	7
18	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	1.0	3

#	ARTICLE	IF	CITATIONS
19	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
20	Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. <i>Nature Cancer</i> , 2021, 2, 1102-1112.	13.2	19
21	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	6.4	59
22	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 709-718.	2.4	44
23	Editorial: Bladder Cancer – A Cinderella Cancer: Advances and Remaining Research Questions. <i>Frontiers in Oncology</i> , 2020, 10, 1749.	2.8	2
24	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e9-735.e15.	1.6	2
25	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. <i>Urology</i> , 2020, 145, 197-203.	1.0	1
26	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1630.	7.1	25
27	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	1.9	9
28	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020, 80, 4476-4486.	0.9	49
29	EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. <i>Oncogene</i> , 2020, 39, 4798-4813.	5.9	29
30	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 936-940.	0.8	3
31	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020, 126, 2132-2138.	4.1	7
32	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020, 3, 420-423.	5.4	29
33	<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2094-2100.	0.9	71
34	<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 977-988.	7.0	104
35	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.8	10
36	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 59-68.	1.9	112

#	ARTICLE	IF	CITATIONS
37	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019, 125, 3164-3171.	4.1	35
38	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019, 380, 2070-2072.	27.0	42
39	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	7.0	71
40	Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. <i>Eur Urol</i> 2019;76:69-70. <i>European Urology</i> , 2019, 76, 71-72.	1.9	2
41	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	3.7	18
42	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019, 25, 2458-2470.	7.0	102
43	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019, 18, 186-191.	0.5	18
44	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
45	Functional profiling of nucleotide Excision repair in breast cancer. <i>DNA Repair</i> , 2019, 82, 102697.	2.8	10
46	Practice Patterns and Outcomes Among Patients With NOMO Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 941-948.	4.9	0
47	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	1.9	72
48	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 157.e15-157.e20.	1.6	6
49	From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation. <i>British Journal of Cancer</i> , 2018, 118, 933-935.	6.4	34
50	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 953-959.	1.3	14
51	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 226-234.	1.9	14
52	Applying Precision Oncology Principles in Radiation Oncology. <i>JCO Precision Oncology</i> , 2018, 2, 1-23.	3.0	12
53	DNA Repair Deficiency and Immunotherapy Response. <i>Journal of Clinical Oncology</i> , 2018, 36, 1710-1713.	1.6	31
54	Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. <i>Annals of Palliative Medicine</i> , 2018, 7, 186-191.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-9.	2.1	7
56	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	2
57	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2018, 19, e683-e695.	10.7	74
58	Quantification of somatic mutation flow across individual cell division events by lineage sequencing. <i>Genome Research</i> , 2018, 28, 1901-1918.	5.5	24
59	Toward Biomarker-Informed Trimodality Therapy (TMT) Approaches for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1417-1419.	0.8	0
60	Post-Prostatectomy Radiation Therapy: Balancing Disease Control and Functional Outcomes. <i>Journal of Urology</i> , 2017, 197, 541-542.	0.4	0
61	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	9.4	519
62	Analysis of patient outcomes following proton radiation therapy for retinoblastoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 44-52.	1.2	12
63	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017, 123, 4832-4840.	4.1	20
64	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <i>Nature Genetics</i> , 2017, 49, 1476-1486.	21.4	427
65	Analysis of somatic microsatellite indels identifies driver events in human tumors. <i>Nature Biotechnology</i> , 2017, 35, 951-959.	17.5	106
66	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 904-911.	0.8	6
67	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	7.0	44
68	DNA Repair Pathway Alterations in Bladder Cancer. <i>Cancers</i> , 2017, 9, 28.	3.7	39
69	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. <i>Nature Genetics</i> , 2016, 48, 600-606.	21.4	352
70	A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance. <i>Cancer Research</i> , 2015, 75, 628-634.	0.9	104
71	Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. <i>Oncoscience</i> , 2015, 2, 942-943.	2.2	14
72	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	9.4	506

#	ARTICLE	IF	CITATIONS
73	Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. <i>Cancer</i> , 2014, 120, 126-133.	4.1	141
74	Dosimetric Consequences of Interobserver Variability in Delineating the Organs at Risk in Gynecologic Interstitial Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 674-681.	0.8	16
75	Proton Radiation Therapy for the Treatment of Retinoblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 863-869.	0.8	46
76	Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. <i>DNA Repair</i> , 2014, 19, 130-134.	2.8	27
77	Hypofractionation in the era of modulated radiotherapy (RT). <i>Breast</i> , 2013, 22, S129-S136.	2.2	7
78	Clinical Controversies: Proton Therapy for Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2013, 23, 109-114.	2.2	18
79	Arginine as a General Acid Catalyst in Serine Recombinase-mediated DNA Cleavage. <i>Journal of Biological Chemistry</i> , 2013, 288, 29206-29214.	3.4	28
80	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. <i>Oral Oncology</i> , 2012, 48, 1025-1030.	1.5	13
81	Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2010, 136, 1226.	1.2	17
82	Orchestrating serine resolvases. <i>Biochemical Society Transactions</i> , 2010, 38, 384-387.	3.4	14
83	Sin Resolvase Catalytic Activity and Oligomerization State are Tightly Coupled. <i>Journal of Molecular Biology</i> , 2010, 404, 16-33.	4.2	16
84	Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. <i>Molecular Microbiology</i> , 2009, 74, 282-298.	2.5	28
85	Architecture of a Serine Recombinase-DNA Regulatory Complex. <i>Molecular Cell</i> , 2008, 30, 145-155.	9.7	55
86	Shaping the <i>Borrelia burgdorferi</i> genome: crystal structure and binding properties of the DNA-bending protein Hbb. <i>Molecular Microbiology</i> , 2007, 63, 1319-1330.	2.5	68